Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
This article was originally published in The Pink Sheet
Executive Summary
Takeda says spinning off its consumer product portfolio into a wholly owned and independent subsidiary will boost its profile in the sector, but all signs continue to point to the firm's Rx operations as its predominant revenue drivers.
You may also be interested in...
Takeda Offloads Emerging Market OTCs to Acino
Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire.
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
Takeda will pay $5.2bn to buy Ariad Pharmaceuticals, the developer of one marketed cancer therapy, Iclusig – but the latter firm's US location and operations could be other important draws for the Japanese big pharma, which has previously announced plans to overhaul its own R&D activities.
Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.